Plasma Protein Profiling to Discern Indolent from Advanced Systemic Mastocytosis

被引:0
作者
Iribarren, Cristina [1 ,2 ,3 ]
Levedahl, Kerstin H. [4 ]
Atanasoai, Ionut [1 ,2 ,3 ,6 ]
Mattsson, Mattias [5 ]
Hoglund, Martin [6 ]
Soderlund, Stina [6 ]
Hagglund, Hans [6 ]
Eriksson, Niclas [8 ,9 ]
Carlson, Marie [7 ]
Nilsson, Gunnar P. [1 ,2 ,3 ,6 ]
机构
[1] Karolinska Univ Hosp, Karolinska Inst, Div Immunol & Allergy, Stockholm, Sweden
[2] Karolinska Univ Hosp, Karolinska Inst, Dept Med, Stockholm, Sweden
[3] Karolinska Univ Hosp, Karolinska Inst, Ctr Mol Med, Stockholm, Sweden
[4] Uppsala Univ, Dept Publ Hlth & Caring Sci, Uppsala, Sweden
[5] Uppsala Univ, Dept Immunol Genet & Pathol, Uppsala, Sweden
[6] Uppsala Univ, Sect Hematol, Uppsala, Sweden
[7] Uppsala Univ, Gastroenterol Res Grp, Uppsala, Sweden
[8] Uppsala Univ, Uppsala Univ, Dept Med Sci, Uppsala, Sweden
[9] Uppsala Univ, Uppsala Clin Res Ctr, Uppsala, Sweden
基金
瑞典研究理事会;
关键词
MAST-CELL ACTIVATION; POLYCYTHEMIA-VERA; MYELOID NEOPLASMS; TRYPTASE LEVELS; SERUM-LEVELS; ANAPHYLAXIS; CLASSIFICATION; INDICATOR; RECEPTOR; ADULTS;
D O I
10.1016/j.jmoldx.2024.05.010
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Mastocytosis is a heterogeneous disorder characterized by abnormal mast cell accumulation, in which the clinical severity may be explained by distinct molecular mechanisms. This study aimed to explore plasma protein biomarkers associated with systemic mastocytosis subtypes, as well as the cellular origin of the identified proteins. Plasma samples from patients with mastocytosis, including cutaneous mastocytosis (CM), indolent systemic mastocytosis (ISM), and advanced systemic mastocytosis (AdvSM), and a reference group of patients with polycythemia vera, were analyzed by Proximity Extension Assay technology targeting 275 proteins. Furthermore, potential cellular origin was explored using an available single-cell RNA-sequencing data set generated from patients with ISM. The study cohort included 16 patients with CM, 92 patients with systemic mastocytosis (ISM, n = 80; AdvSM, n = 12), and 60 patients with polycythemia vera. A principal component analysis based on 275 plasma proteins revealed one cluster of patients with CM and ISM that was separated from patients with AdvSM. Up to 29 proteins were associated with distinct severe activity in patients with systemic mastocytosis (ISM versus AdvSM), including IL-1 receptor type 1 (IL-1RT1) and tumor necrosis factor ligand superfamily member 13B (TNFSF13B) (q < 0.01). Furthermore, single-cell RNA-sequencing analysis from ISM-derived bone marrow cells revealed that the mRNA for the identified proteins was not exclusive of mast cells. Distinct plasma protein profiles show potential to refine ISM and AdvSM diagnoses, possibly reflecting differences in pathogenic mechanisms and diverse clinical manifestations.
引用
收藏
页码:792 / 804
页数:13
相关论文
共 46 条
  • [1] A Distinct Faecal Microbiota and Metabolite Profile Linked to Bowel Habits in Patients with Irritable Bowel Syndrome
    Ahluwalia, Bani
    Iribarren, Cristina
    Magnusson, Maria K.
    Sundin, Johanna
    Clevers, Egbert
    Savolainen, Otto
    Ross, Alastair B.
    Tornblom, Hans
    Simren, Magnus
    Ohman, Lena
    [J]. CELLS, 2021, 10 (06)
  • [2] Soluble stem cell factor receptor (CD117) and IL-2 receptor alpha chain (CD25) levels in the plasma of patients with mastocytosis: relationships to disease severity and bone marrow pathology
    Akin, C
    Schwartz, LB
    Kitoh, T
    Obayashi, H
    Worobec, AS
    Scott, LM
    Metcalfe, DD
    [J]. BLOOD, 2000, 96 (04) : 1267 - 1273
  • [3] LAG3 (CD223) as a cancer immunotherapy target
    Andrews, Lawrence P.
    Marciscano, Ariel E.
    Drake, Charles G.
    Vignali, Dario A. A.
    [J]. IMMUNOLOGICAL REVIEWS, 2017, 276 (01) : 80 - 96
  • [4] The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia
    Arber, Daniel A.
    Orazi, Attilio
    Hasserjian, Robert
    Thiele, Jurgen
    Borowitz, Michael J.
    Le Beau, Michelle M.
    Bloomfield, Clara D.
    Cazzola, Mario
    Vardiman, James W.
    [J]. BLOOD, 2016, 127 (20) : 2391 - 2405
  • [5] Homogenous 96-Plex PEA Immunoassay Exhibiting High Sensitivity, Specificity, and Excellent Scalability
    Assarsson, Erika
    Lundberg, Martin
    Holmquist, Goeran
    Bjoerkesten, Johan
    Thorsen, Stine Bucht
    Ekman, Daniel
    Eriksson, Anna
    Dickens, Emma Rennel
    Ohlsson, Sandra
    Edfeldt, Gabriella
    Andersson, Ann-Catrin
    Lindstedt, Patrik
    Stenvang, Jan
    Gullberg, Mats
    Fredriksson, Simon
    [J]. PLOS ONE, 2014, 9 (04):
  • [6] Inflammation and thrombosis in essential thrombocythemia and polycythemia vera: different role of C-reactive protein and pentraxin 3
    Barbui, Tiziano
    Carobbio, Alessandra
    Finazzi, Guido
    Vannucchi, Alessandro M.
    Barosi, Giovanni
    Antonioli, Elisabetta
    Guglielmelli, Paola
    Pancrazzi, Alessandro
    Salmoiraghi, Silvia
    Zilio, Pio
    Ottomano, Cosimo
    Marchioli, Roberto
    Cuccovillo, Ivan
    Bottazzi, Barbara
    Mantovani, Alberto
    Rambaldi, Alessandro
    [J]. HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2011, 96 (02): : 315 - 318
  • [7] Massive release of TH2 cytokines induced a cytokine storm during a severe mast cell activation event in a patient with indolent systemic mastocytosis
    Boehm, Thomas
    Ristl, Robin
    Muehlbacher, Jakob
    Valent, Peter
    Wahrmann, Markus
    Jilma, Bernd
    [J]. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2022, 150 (02) : 406 - +
  • [8] Random forests
    Breiman, L
    [J]. MACHINE LEARNING, 2001, 45 (01) : 5 - 32
  • [9] IL-6 levels predict disease variant and extent of organ involvement in patients with mastocytosis
    Brockow, K
    Akin, C
    Huber, M
    Metcalfe, DD
    [J]. CLINICAL IMMUNOLOGY, 2005, 115 (02) : 216 - 223
  • [10] Levels of mast-cell growth factors in plasma and in suction skin blister fluid in adults with mastocytosis: Correlation with dermal mast-cell numbers and mast-cell tryptase
    Brockow, K
    Akin, C
    Huber, M
    Scott, LM
    Schwartz, LB
    Metcalfe, DD
    [J]. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2002, 109 (01) : 82 - 88